Citation 88151

DUAN,H: TAKAISHI,Y: MOMOTA,H: OHMOTO,Y: TAKI,T: TORI,M: TAKAOKA,S: JIA,Y: LI,D:. (2001). IMMUNOSUPPRESSIVE TERPENOIDS FROM EXTRACTS OF TRIPTERYGIUM WILFORDII.. 57(40)

Citation Details

Title	IMMUNOSUPPRESSIVE TERPENOIDS FROM EXTRACTS OF TRIPTERYGIUM WILFORDII.
Authors	DUAN,H: TAKAISHI,Y: MOMOTA,H: OHMOTO,Y: TAKI,T: TORI,M: TAKAOKA,S: JIA,Y: LI,D:
Year	2001
Volume	57
Issue	40

Summary

Year: 2001

Journal: Unknown

Organisms and Their Experiments (1)

Tripterygium wilfordii (CELASTRACEAE)

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	Not specified	VOUCHER SPECIMEN REPORTED FOR	None	None
2	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDX-RAY CHRYSTALLOGRAPHIC STUDIESINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	KAURANE,16-ALPHA-HYDROXY-19-20-EPOXY-19(R)-ETHOXY:	None
3	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-20-EPOXY-19(R)-ETHOXY:	INACTIVE
4	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-20-EPOXY-19(R)-ETHOXY:	WEAK ACTIVITY
5	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-20-EPOXY-19(R)-ETHOXY:	INACTIVE
6	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-20-EPOXY-19(R)-ETHOXY:	WEAK ACTIVITY
7	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-20-EPOXY-19(R)-ETHOXY:	INACTIVE
8	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-20-EPOXY-19(R)-ETHOXY:	INACTIVE
9	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	KAURANE,16-ALPHA-HYDROXY-19-20-EPOXY-19(S)-ETHOXY:	None
10	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	KAURANE,16-ALPHA-HYDROXY-19-2-EPOXY-20(R)-ETHOXY:	None
11	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-2-EPOXY-20(R)-ETHOXY:	INACTIVE
12	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-2-EPOXY-20(R)-ETHOXY:	INACTIVE
13	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-2-EPOXY-20(R)-ETHOXY:	INACTIVE
14	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-2-EPOXY-20(R)-ETHOXY:	ACTIVE
15	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-2-EPOXY-20(R)-ETHOXY:	WEAK ACTIVITY
16	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE,16-ALPHA-HYDROXY-19-2-EPOXY-20(R)-ETHOXY:	INACTIVE
17	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	KAURANE,16-ALPHA-HYDROXY-19-20-EPOXY-20(R)-HYDROXY:	None
18	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	KAURAN-19-20-DIOIC ACID,16-ALPHA-HYDROXY:	None
19	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	MANOYL OXIDE-18-OIC ACID,13-EPI-19-NOR:	None
20	Not specified	UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	ABIETA-8-11-13-TRIENE,3-BETA-11-19-TRIHYDROXY-14-METHOXY:	None
21	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	URS-12-EN-30-OIC ACID,22-BETA-HYDROXY-3-OXO:	None
22	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	URS-12-EN-30-OIC ACID,22-BETA-HYDROXY-3-OXO:	INACTIVE
23	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	URS-12-EN-30-OIC ACID,22-BETA-HYDROXY-3-OXO:	INACTIVE
24	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	URS-12-EN-30-OIC ACID,22-BETA-HYDROXY-3-OXO:	INACTIVE
25	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	URS-12-EN-30-OIC ACID,22-BETA-HYDROXY-3-OXO:	WEAK ACTIVITY
26	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	URS-12-EN-30-OIC ACID,22-BETA-HYDROXY-3-OXO:	INACTIVE
27	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	URS-12-EN-30-OIC ACID,22-BETA-HYDROXY-3-OXO:	INACTIVE
28	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	URS-12-EN-30-OIC ACID,28-HYDROXY-3-OXO:	None
29	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	OLEAN-12-ENE-22-29-LACTONE,2-ALPHA-3-BETA-DIHYDROXY:	None
30	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-22-29-LACTONE,2-ALPHA-3-BETA-DIHYDROXY:	INACTIVE
31	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-22-29-LACTONE,2-ALPHA-3-BETA-DIHYDROXY:	WEAK ACTIVITY
32	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-22-29-LACTONE,2-ALPHA-3-BETA-DIHYDROXY:	INACTIVE
33	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-22-29-LACTONE,2-ALPHA-3-BETA-DIHYDROXY:	ACTIVE
34	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-22-29-LACTONE,2-ALPHA-3-BETA-DIHYDROXY:	WEAK ACTIVITY
35	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-22-29-LACTONE,2-ALPHA-3-BETA-DIHYDROXY:	WEAK ACTIVITY
36	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	OLEAN-12-EN-29-OIC ACID,28-HYDROXY-3-OXO:	None
37	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,28-HYDROXY-3-OXO:	INACTIVE
38	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,28-HYDROXY-3-OXO:	WEAK ACTIVITY
39	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,28-HYDROXY-3-OXO:	INACTIVE
40	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,28-HYDROXY-3-OXO:	WEAK ACTIVITY
41	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,28-HYDROXY-3-OXO:	INACTIVE
42	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,28-HYDROXY-3-OXO:	INACTIVE
43	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	OLEAN-12-EN-29-OIC ACID,3-BETA-28-DIHYDROXY:	None
44	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	OLEAN-12-EN-29-OIC ACID,3-ALPHA-28-DIHYDROXY:	None
45	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,3-ALPHA-28-DIHYDROXY:	INACTIVE
46	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,3-ALPHA-28-DIHYDROXY:	INACTIVE
47	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,3-ALPHA-28-DIHYDROXY:	INACTIVE
48	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,3-ALPHA-28-DIHYDROXY:	WEAK ACTIVITY
49	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,3-ALPHA-28-DIHYDROXY:	INACTIVE
50	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-EN-29-OIC ACID,3-ALPHA-28-DIHYDROXY:	INACTIVE
51	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	FRIEDELAN METHYL ESTER,29-NOR: 2-BETA-22-BETA-DIHYDROXY-3-21-DIOXO-24-CARBOXYL:	None
52	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	OLEAN-12-20(30)-DIENE,21-BETA-28-DIHYDROXY-3-OXO: 29-NOR:	None
53	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	OLEAN-1-12-DIEN-29-OIC ACID,2-22-BETA-DIHYDROXY-3-OXO:	None
54	Not specified	UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	FRIEDOOLEAN-29-OIC ACID,24-NOR-D: A: 2-3-DIHYDROXY-1-3-5(10)-7-TETRAENE-6-BETA(1'-HYDROXY-ETHYL):	None
55	Not specified	UV SPECTRUM GIVEN FORMASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	FRIEDOOLEAN-29-OIC ACID,24-NOR-D: A: 2-3-DIHYDROXY-1-3-5(10)-7-TETRAENE-6-ALPHA(1'-HYDROXY-ETHYL):	None
56	Not specified	MASS-SPECTRAL FRAGMENTATION REPORTEDPMR SPECTRUM REPORTEDCMR SPECTRUM REPORTEDINFRARED SPECTRUM REPORTED FORISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	OLEAN-12-ENE-2-3-DIOIC ACID-3-METHYL ESTER,2-3-SECO-22-29-LACTONE	None
57	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-2-3-DIOIC ACID-3-METHYL ESTER,2-3-SECO-22-29-LACTONE	ACTIVE
58	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-2-3-DIOIC ACID-3-METHYL ESTER,2-3-SECO-22-29-LACTONE	ACTIVE
59	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-2-3-DIOIC ACID-3-METHYL ESTER,2-3-SECO-22-29-LACTONE	ACTIVE
60	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-2-3-DIOIC ACID-3-METHYL ESTER,2-3-SECO-22-29-LACTONE	ACTIVE
61	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-2-3-DIOIC ACID-3-METHYL ESTER,2-3-SECO-22-29-LACTONE	ACTIVE
62	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	OLEAN-12-ENE-2-3-DIOIC ACID-3-METHYL ESTER,2-3-SECO-22-29-LACTONE	ACTIVE
63	Not specified	ISOLATION AND IDENTIFICATION OF	KAURANE-17-19-DIOIC ACID	None
64	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE-17-19-DIOIC ACID	INACTIVE
65	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE-17-19-DIOIC ACID	INACTIVE
66	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE-17-19-DIOIC ACID	INACTIVE
67	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE-17-19-DIOIC ACID	WEAK ACTIVITY
68	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE-17-19-DIOIC ACID	INACTIVE
69	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAURANE-17-19-DIOIC ACID	INACTIVE
70	Not specified	ISOLATION AND IDENTIFICATION OF	KAURANE-16-19-20-TRIOL	None
71	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOBENZENE J	INACTIVE
72	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOBENZENE J	WEAK ACTIVITY
73	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOBENZENE J	INACTIVE
74	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOBENZENE J	ACTIVE
75	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOBENZENE J	INACTIVE
76	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOBENZENE J	WEAK ACTIVITY
77	Not specified	ISOLATION AND IDENTIFICATION OF	TRIPTERININLABD-TRANS-13-ENE-8-ALPHA-15-DIOL	None
78	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOLIDE	ACTIVE
79	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOLIDE	ACTIVE
80	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOLIDE	ACTIVE
81	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOLIDE	ACTIVE
82	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOLIDE	ACTIVE
83	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOLIDE	ACTIVE
84	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTODIOLIDE	ACTIVE
85	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTODIOLIDE	ACTIVE
86	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTODIOLIDE	ACTIVE
87	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTODIOLIDE	ACTIVE
88	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTODIOLIDE	ACTIVE
89	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTODIOLIDE	ACTIVE
90	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOCHLOROLIDE	ACTIVE
91	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOCHLOROLIDE	ACTIVE
92	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOCHLOROLIDE	ACTIVE
93	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOCHLOROLIDE	ACTIVE
94	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOCHLOROLIDE	ACTIVE
95	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TRIPTOCHLOROLIDE	ACTIVE
96	Not specified	ISOLATION AND IDENTIFICATION OF	LABD-14-EN-19-OIC AICD,14-15-DIHYDROXY-8-13-EPOXY:TRIPTOTRITERPENIC ACID BWILFORLIDE ACORSOLIC ACIDREGEOL C	None
97	INTERLEUKIN-1-BETA-SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	WILFORIC ACID A	ACTIVE
98	INTERLEUKIN 8 SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	WILFORIC ACID A	INACTIVE
99	TUMOR NECROSING FACTOR-ALPHA RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	WILFORIC ACID A	INACTIVE
100	INTERLEUKIN-2 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	WILFORIC ACID A	ACTIVE
101	INTERLEUKIN-4 RELEASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	WILFORIC ACID A	INACTIVE
102	INTERFERON-GAMMA SECRETION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	WILFORIC ACID A	WEAK ACTIVITY

Citation 88151

Citation Details

Summary

Organisms and Their Experiments (1)

Tripterygium wilfordii (CELASTRACEAE)

Show SPARQL Queries (1)

Query 1